Meeting
2013 ASCO Annual Meeting
Phase III trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients (pts) with CD30+ mature T-cell lymphomas (MTCL).
Authors
Owen A. O'Connor
Columbia University Medical Center / New York Presbyterian Hospital, New York, NY
Owen A. O'Connor , Barbara Pro , Tim Illidge , Lorenz H. Trumper , Emily K. Larsen , Dana A. Kennedy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Lymphoma
Clinical Trial Registration Number
NCT01777152
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS8611)
DOI
10.1200/jco.2013.31.15_suppl.tps8611
Abstract #
TPS8611
Poster Bd #
56H
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Phase III trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients (pts) with CD30+ mature T-cell lymphomas (MTCL).
First Author: Owen A. O'Connor
Poster
2014 ASCO Annual Meeting
Phase 3 trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients (pts) with CD30+ mature T-cell lymphomas (MTCL).
First Author: Owen A. O'Connor
Poster
2020 ASCO Virtual Scientific Program
Comparison of efficacy and safety with obinutuzumab plus chemotherapy versus rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: Updated results from the phase III Gallium Study.
First Author: William Townsend
First Author: Ranjana H. Advani